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Introduction: Prostate cancer bone metastasis occurs in 50-90% of men with advanced disease for which there is
no cure. Bone metastasis leads to debilitating fractures and severe bone pain. It is associated with therapy resistance
and rapid decline. Androgen deprivation therapy (ADT) is standard of care for advanced prostate cancer, however,
bone metastatic prostate cancer (PCa) often becomes resistant to ADT. There are few pre-clinical models to
understand the interaction between the bone microenvironment and prostate cancer. Here we report the castrate
resistant growth in the bone niche of PCSD1, a patient-derived intra-femoral xenograft model of prostate bone
metastatic cancer treated with the anti-androgen, bicalutamide.
Methods: PCSD1 bone-niche model was derived from a human prostate cancer femoral metastasis resected during
hemiarthroplasty and serially transplanted into Rag2−/−;γc−/− mice intra-femorally (IF) or sub-cutaneously (SC). At
5 weeks post-transplantation mice received bicalutamide or vehicle control for 18 days. Tumor growth of PCSD1
was measured with calipers. PSA expression in PCSD1 xenograft tumors was determined using quantitative RT-PCR
and immunohistochemistry. Expression of AR and PSMA, were also determined with qPCR.
Results: PCSD1 xenograft tumor growth capacity was 24 fold greater in the bone (intra-femoral, IF) than in the soft
tissue (sub-cutaneous, SC) microenvironment. Treatment with the anti-androgen, bicalutamide, inhibited tumor
growth in the sub-cutaneous transplantation site. However, bicalutamide was ineffective in suppressing PCSD1
tumor growth in the bone-niche. Nevertheless, bicalutamide treatment of intra-femoral tumors significantly reduced
PSA expression (p < =0.008) and increased AR (p < =0.032) relative to control.
Conclusions: PCSD1 tumors were castrate resistant when growing in the bone-niche compared to soft tissue.
Bicalutamide had little effect on reducing tumor burden in the bone yet still decreased tumor PSA expression and
increased AR expression, thus, this model closely recapitulated castrate-resistant, human prostate cancer bone
metastatic disease. PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study bone
metastatic disease and for pre-clinical drug development of novel therapies for inhibiting therapy resistant prostate
cancer growth in the bone-niche.
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Prostate cancer is the second leading cause of cancer-
related death in men despite advances in prostate cancer
management [1]. Since the PSA Era, clinically localized
prostate cancer at diagnosis has increased from 73% to
91%, allowing more men to be cured of their organ con-
fined prostate cancer, while metastatic disease at diagno-
sis has decreased from 6.6% to 4.0% [2]. For the majority
of those men who are not cured or who are diagnosed
late, however, prostate cancer will metastasize to bone
leading to pain, pathologic fractures, spinal compression
and rapid decline [3]. Improvements in progression-free
survival and cancer-specific mortality rates have been at-
tributed to both earlier detection and improved treat-
ments [2], but the number of men who fail treatment or
are diagnosed at later stages is expected to rise again fol-
lowing the USPSTF recommendations and possible de-
creased utilization of PSA screening.
For recurrent prostate cancer or metastatic disease on
presentation, NCCN guidelines recommend starting an-
drogen deprivation therapy (ADT) with close monitoring
[4]. Bicalutamide, one form of androgen deprivation, acts
as a competitive inhibitor of androgens by binding the
androgen receptor (AR), impairing DNA binding to An-
drogen Response Elements (ARE), and impairing recruit-
ment of co-activators necessary for testosterone or DHT
to impart their proliferative effect on responsive cells
[5]. At presentation, if metastatic men were started on
ADT, 5-year survival increased from 10% to 19% [6].
Unfortunately, prostate cancer bone metastases often be-
come resistant to ADT [7].
Next generation ADTs, chemotherapy, and radiophar-
maceuticals, along with supportive care, comprises the
next stage of care. There are two FDA-approved next
generation ADTs, abiraterone acetate and enzalutamide.
Abiraterone inhibits the intra-tumoral androgen produc-
tion by irreversibly binding the CYP17A1 steroidogenic
enzyme in an antagonistic fashion, while enzalutamide
binds the androgen receptor with strong affinity and di-
minishes the nuclear translocation of the androgen re-
ceptor. Both have been shown to improve survival
[8-11], however, eventually, resistance develops to these
as well, perhaps through mutations in the androgen re-
ceptor [12]. In fact, in recent clinical trials, the effects of
next generation ADT on bone scans were sometimes in-
consistent with the favorable biochemical PSA response
and patients progressed despite having a biochemical re-
sponse, that is, a decrease in PSA [13].
There is currently no curative treatment for prostate
cancer bone metastases [3]. There are few models to
study the mechanisms in which resistance develops
within the bone niche and in which to test novel therap-
ies [12]. We have previously described the development
and characterization of PCSD1 (Prostate Cancer SanDiego 1), a novel patient-derived intra-femoral xenograft
model of prostate bone metastatic cancer derived from a
surgical specimen from the hip of a patient who was
treated with prostate radiation followed by androgen
deprivation therapy (ADT) for 2 years in the process of
developing castrate resistance [14]. Here, we report an
in vivo challenge with ADT in the PCSD1 model and
characterize the results to understand further the mech-
anisms of castration resistance in the bone niche.
Methods
Patient-derived xenograft model of bone metastatic
prostate cancer
PCSD1 is a patient-derived xenograft model previously
described in Raheem et al. [14]. Approval was received
from the UCSD institutional review board (IRB) to col-
lect surgical bone metastatic prostate cancer specimens
for research purposes. The PCSD1 surgical prostate can-
cer bone metastasis specimen was donated by a man
with high risk (Gleason 5 + 5) prostate cancer found to
be locally advanced (T3a) and stage 4 (2 of 5 positive
lymph nodes, or N1) but without imaging evidence of
metastasis underwent prostatectomy with adjuvant ADT
and radiation to his prostatic fossa and pelvic lymph
nodes. However, approximately 2 years later, he pro-
gressed to castrate resistant bone metastatic prostate
cancer. He presented with right hip pain and fracture
and underwent palliative hemiarthroplasty at which time
the surgical prostate cancer bone metastasis was ob-
tained and transplanted into the femurs of 6–8 week old
Rag2−/−;γc
−/− as described in Raheem et al. [14]. The
PCSD1 cells used for experiments herein were freshly
isolated from low passage PCSD1 intra-femoral xeno-
graft tumors prepared as described in Raheem et al. [14]
and re-suspended 1:1 in high concentration Matrigel
(BD Biosciences, Inc.) then injected into 6–8 week old
Rag2−/−;γc
−/− mice either intra-femorally (IF), 50,000 cells
per injection of 15 μl into the right femur or one million
cells re-suspended 1:1 in high concentration Matrigel
per injection of 100 μl sub-cutaneously (SC) in the right
flank. All animal protocols were performed under a
UCSD animal welfare IACUC approved protocol.
PCSD1 GLF-lentiviral transduction and in vivo Bioluminescent
Imaging (IVIS)
PCSD1 cells were freshly isolated from low passage
intra-femoral xenograft tumors and single cell suspen-
sions prepared as previously described [14]. Cells were
then transduced with a GFP-luciferase expressing lenti-
viral vector (GLF), a kind gift from Dr. Catriona Jamieson,
UCSD, according to established methods [15,16]. Cells
were cultured with virus for 72 hours, sorted by flow cy-
tometry for green fluorescent protein (GFP) positive
cells on FACSAria. GFP + cells were resuspended in
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cells/ml and mixed 1:1 in high concentration Matrigel
(BD Biosciences, Inc.) and injected into 6–8 week old
male Rag2−/−γc
−/− mice either intra-femorally (IF; n = 10)
(5 × 104 cells in 15 μl per mouse) or sub-cutaneously (SC;
n = 10) (1 × 106 cells in 100 μl per mouse). Mice were
monitored weekly for health, body weight and appearance
of palpable tumor. Tumor volume was assessed using an
in vivo bioluminescence imaging system (IVIS 200; Caliper
Inc.) just before euthanizing mice for tissue and tumor
collection at the termination of the experiment. Mice were
sacrificed at 18 days of treatment or when tumors reached
length reached 1.5 cm, maximal allowable size according
to UCSD ACP standards.Anti-androgen treatment and tumor growth of PCSD1
xenografts
Mice were monitored for health, body weight and ap-
pearance of palpable tumor. At 5 weeks after PCSD1
transplantation, the injected mice received an 18-day
treatment of daily oral gavage with Bicalutamide (Sigma
B9061) 50 mg/kg/day, or vehicle control (0.9% benzyl al-
cohol (Sigma 402834), 1% Tween-80 (Sigma P4780),
0.5% Methylcellulose (Sigma M0512)). Twice weekly
mice were weighed, health status was recorded and the
length and width of tumors were measured with calipers.
Tumor volume was calculated using the formula:
Tumor volume (mm3) = (length (mm) x width (mm)2) /
0.52) [17].Quantitative RT-PCR
RNA was extracted from flash frozen tissue of xenograft
tumors harvested from mice injected IF or SC and treated
with Bicalutamide or vehicle. The Qiagen RNeasy kit was
used for RNA extraction according to manufacturer rec-
ommended protocol [14]. RNA was quantified using
NanoDrop. cDNA was synthesized using Superscript III
(Invitrogen, by Life Technologies Inc.) and used for quan-
titative PCR using Light Cycler 480 SYBR-Green I Master
kit (Roche Inc). Custom-designed human-specific primers
were used for human prostate specific antigen (PSA) and
human androgen receptor (AR) were described in Raheem
et al. [14]. Primers for human prostate specific membrane
antigen (PSMA) were 5-GAG GAG CTT TGG AAC ACT
GA-3 for the forward primer (PSMA-F1) and 5-CCT
CTG CCC ACT CAG TAG AA-3 for the reverse primer
(PSMA-R1) (ValueGene Inc.). PSMA, PSA and AR human
specific primers were used for PCR amplification of cDNA
synthesized with reverse transcriptase (RT+) or without
(RT-) and confirmed by DNA sequencing of correctly
sized bands. Human and mouse-specific GAPDH or
ACTB-specific primers were used as internal reference
controls for qPCR [14]. Positive and negative control celllines included the prostate cancer cell lines, LNCaP,
LAPC4, human B cell line, Raji, and 293 T cell lines.
Immunohistochemistry
Intra-femoral tumors were fixed in 10% formalin, decal-
cified with 10% EDTA, embedded in OCT and frozen in
isopentane/dry ice bath for cryosections or paraffin em-
bedded as described in Raheem et al. [14]. Subcutaneous
tumors were fresh frozen in OCT or 10% formalin-fixed
and embedded in paraffin at the time of harvest. IF and
SC sections were H&E and immunostained with anti-
PSA, 1:500 (DAKO) [14]. Images were captured using
the Aperio ScanScope and Keyence digital microscope.
Quantitation of PSA staining in FFPE sections was
performed using The Spectrum Analysis algorithm pack-
age and ImageScope Analysis software as described in
Woo et al. [18] with the modifications that five fields of
view were randomly selected in Aperio ScanScope digital
images at 20 X magnification in each of three different tu-
mors in each treatment group. Total anti-PSA stained
area/total analysis area was calculated for each field of
view.
Statistical data analysis
Comparative statistics included non parametric Mann–
Whitney U test and Kruskal-Wallis to assess for signifi-
cance using IBM SPSS Statistics for Windows (Version
21.0.2012 Armonk, NY: IBM Corp). Mouse weights and
tumor weights were compared between vehicle and bica-
lutamide groups. The Mann–Whitney U test was used to
compare continuous parameters. Kruskal-Wallis test was
used to compare parameters between four groups. The re-
sults were considered significant at a p-value of <0.05. All
statistical analyses were performed using IBM SPSS Statis-
tics for Windows (Version 21.0.2012 Armonk, NY).
Results
The effect of androgen deprivation therapy (ADT) on
prostate cancer growth in the bone versus soft tissue
microenvironment was tested in the patient-derived xeno-
graft model, PCSD1. Prostate cancer bone metastasis-
derived PCSD1 cells were injected directly into the endos-
teal space of the right femurs (intra-femorally, IF) or under
the skin on the right flanks (sub-cutaneously, SC) of 6-8-
week old Rag2−/−γc
−/− mice. Treatment with 10 mg/kg/day
bicalutamide in a previous experiment had no effect on
intra-femoral PCSD1 tumor growth (data not shown).
Therefore, a higher dose of bicalutamide (50 mg/kg/day)
was tested in these experiments. Treatment with high-
dose bicalutamide or vehicle control by daily oral gavage
was started when tumors were first palpable at 5 to
5.5 weeks after tumor cell transplantation and continued
for 18 days. Mouse total body weights and tumor sizes
were measured biweekly. In all the figures, the vehicle
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treatment is represented as red. Total body weights of
mice did not change significantly over the treatment
period in any of the treatment groups (Figure 1A and B).
Differences were not statistically significant when total
body weights were compared between vehicle and bicalu-
tamide groups (Final body weight p = 0.095). In vivo
bioluminescent imaging (IVIS) of tumors was performed
in mice just before termination of the experiment and
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Figure 1 Testing the anti-androgen response of the PCSD1 prostate c
Rag2−/−;γc−/− mice were injected with PCSD1 xenograft tumor cells either in
post-transplantation with bicalutamide or vehicle control for 18 days, B.) C
Mice were weighed biweekly (SC) and weekly (IF); Vehicle control (blue line
n = 5, IF n = 5). Differences in mouse weights were not statistically significa
C.) In vivo bioluminescent imaging (IVIS) of PCSD1 tumors which stably exp
end of treatment with vehicle and bicalutamide demonstrated preferential
figures, results of vehicle treatment are represented in blue and bicalutamiPCSD1 Tumor growth in the bone micro-environment was
significantly greater than in the sub-cutaneous niche
Tumor growth capacity was compared between the sub-
cutaneous versus intra-femoral tumor microenvironments.
Tumor volume was measured using calipers biweekly.
Strikingly, injection of just 50,000 PCSD1 cells into the
femur (IF) resulted in the same sized tumor as the sub-
cutaneous (SC) injection of one million PCSD1 cells in the
same time period. As shown in Figure 2A, the tumor
growth capacity was determined as a function of the num-
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ancer xenograft model in bone versus sub-cutaneous niches. A.)
tra-femorally (IF) or sub-cutaneously (SC) then treated at 5 weeks
hanges in total body weights were equivalent in all treatment groups.
, SC n = 4 mice, IF n = 5), Bicalutamide 50 mg/kg/day, (red line, SC
nt (Mann Whitney test, p = 0.095), Error bars denote standard error.
ressed GFP-luciferase: SC (left panel) and IF tumors (right panel) at the
castrate-resistance of the PCSD1 tumors in the bone niche. In all the
































































Figure 2 PCSD1 tumor growth was significantly greater in the bone niche compared to sub-cutaneous niche. Tumor growth was compared
as a function of tumor volume per cell injected at transplantation. The same tumor volumes were attained in the same time when 50,000 PCSD1
cells were injected intra-femorally as when one million PCSD1 cells were injected sub-cutaneously. A. Final tumor volume of sub-cutaneous (SC) and
intra-femoral (IF) tumors per initially injected cell number. Blue bars show final tumor volume per injected cell in mice treated with vehicle control,
Red bars are for mice treated with bicalutamide. There was a 24-fold greater tumor volume per IF-injected cell compared to SC-injected cell in vehicle
treated mice and a 16-fold greater tumor volume in bicalutamide treated IF versus SC injected tumors. B. Final tumor volume of sub-cutaneous (SC)
tumors per initially injected cell number. Error bars show standard deviation.
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greater final tumor volume per injected PCSD1 cell in the
bone (IF) than in sub-cutaneous (SC) location in mice
treated with vehicle control. There was also a 16-fold
greater growth of the bicalutamide-treated tumors in the
bone-niche than the sub-cutaneous niche. The mean
tumor volume per injected cells was greater in the vehicle
treated compared to bicalutamide treated mice for both
SC and IF transplants, however, this was within standard
deviation of the experiments as shown by the error bars.
An expanded plot of the sub-cutaneous tumors them-
selves is shown in Figure 2B. While the means of the
tumor volume per injected cell of the bicalutamide treatedtumors is lower than the vehicle treated tumors the differ-
ences are not statistically significant. Therefore, injection
of PCSD1 cells into the bone led to a significantly greater
capacity for tumor growth in the bone than in the sub-
cutaneous niche.
Intra-femoral PCSD1 tumor growth was more resistant to
treatment with the anti-androgen, bicalutamide
Tumor growth over the time of treatment was compared
between vehicle and bicalutamide-treated mice. Tumor
volume was measured using calipers biweekly. At the
termination of the experiment sub-cutaneous (SC) tu-
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Figure 3 Bicalutamide treatment inhibited the growth of sub-cutaneous (SC) PCSD1 tumors more than intra-femoral (IF) PCSD1 tumors.
PCSD1 xenograft cells were directly injected either sub-cutaneously (SC) or intra-femorally (IF) into Rag2−/−;γc
−/− mice. A.) Wet tumor weight
of bicalutamide treated SC tumors was reduced. B.) Bicalutamide reduced average wet SC tumor weight by half. C.) Bicalutamide (red line)
suppressed PCSD1 tumor growth in mice with sub-cutaneously transplanted tumors compared to vehicle treatment (blue line). D.) Bicalutamide (red
line) did not significantly suppress PCSD1 tumor growth in mice with intra-femorally transplanted tumors compared to vehicle treatment (blue line).
Length and width of tumors were measured in mm using calipers and used to calculate tumor volume. Vehicle control (blue, SC n = 4 mice, IF n = 5),
Bicalutamide 50 mg/kg/day, (red, SC n = 5, IF n = 5) E.) Waterfall plot of percent change in final tumor volume at termination, Day 18, from
baseline, the tumor volume treatment Day 1. Blue bars are for individual mice treated with vehicle control, Red bars are for individual mice
treated with bicalutamide. Error bars denote standard error.
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mors was almost half of the vehicle-treated SC tumors
(Figure 3B). Wet weights of intra-femoral (IF) tumors were
not included in this analysis, however, because the femur
bone was still encased within the excised tumor mass.
To compare tumor growth rates between groups, bi-
weekly caliper measurements were plotted against time
as shown in Figure 3C. The treatment of the SC tumors
was started 0.5 weeks earlier in the post-transplantation
time course than for the IF tumors. Nevertheless, the
total treatment time of 18 days was the same for both
SC (4.5 week to 7 weeks post-transplantation) and IF tu-
mors (5 weeks to 7.5 weeks post-transplantation) and
the tumor volumes and growth rates for SC and IF tu-
mors at both time points of 4.5 and 5 weeks were
equivalent. Bicalutamide treatment led to growth inhib-
ition in SC tumors compared to vehicle treated SC
tumors (Figure 3C). The Mann–Whitney statistical ana-
lysis indicated that differences in tumor volumes trended
towards significance as seen in the p values for each
time point in Table 1. In comparison, bicalutamide had
almost no effect on the growth rates of IF tumors com-
pared to vehicle (Figure 3D). The percent change in each
tumor from Day 1 of treatment (baseline) until termin-
ation at 18 days of treatment was greater in the SC tu-
mors than the IF tumors as shown in the waterfall plot
in Figure 3E. Therefore, PCSD1 tumor growth in the
bone microenvironment was more resistant to bicaluta-
mide than in soft tissue.
Bicalutamide reduced expression of Prostate Specific
Antigen (PSA) RNA in intra-femoral (IF) PCSD1 tumors
The bicalutamide mechanism of action is to inhibit the
activity of the androgen receptor (AR) thereby suppress-
ing the viability and proliferation of prostate cancer cells
that depend on it. To determine the effect of bicaluta-
mide treatment on AR activity in PCSD1 tumors the ex-
pression of AR-target genes was measured using
Quantitative RT-PCR (Q-PCR) on RNA extracted from
dissected PCSD1 tumors that were transplanted either
sub-cutaneously or intra-femorally. Q-PCR was per-
formed on the AR-target gene, prostate specific antigenTable 1 Statistical analysis of PCSD1 tumor volumes at each t
IF Tumor Volume at Week: 5 6
Vehicle 760.511232 1360.8478
Bicalutamide 699.844704 1614.89276
p value 0.841 0.151
SC Tumor Volume at Week: 5 5.5
Vehicle 791.58599 1529.06611
Bicalutamide 717.73988 1005.140552
p value 0.905 0.19(PSA, Kallikrein-3), and AR itself. Q-PCR was normal-
ized to human-specific GAPDH expression levels. The
same amount of RNA (1 μg) was used for cDNA synthe-
sis and yield of RNA was similar per PCSD1 and LNCaP
cell. The individual mouse numbers are shown on the
horizontal axes ranked from low to high PSA level
and are in the same order for all three Q-PCR plots,
Figure 4A-C. As shown in Figure 4A, bicalutamide treat-
ment reduced PSA expression in PCSD1 tumors in the
femur even though tumor growth was not significantly
reduced (Figure 3D and E). PSA expression in intra-
femoral (IF) PCSD1 tumors in vehicle treated mice was
comparable to that of the prostate cancer cell line, LNCaP.
In contrast, the PSA levels in PCSD1 sub-cutaneous (SC)
tumors in both vehicle and bicalutamide-treated mice
were significantly lower than in IF PCSD1 tumors and
LNCaP. Bicalutamide treatment did not change levels of
PSA in SC PCSD1 tumors. Quantitative PCR analysis of
AR levels in PCSD1 tumors showed that bicalutamide
treatment increased AR expression in both IF and in SC
tumors. The level of PSMA, which is highly expressed in
many advanced prostate cancers including PCSD1, was
unchanged in bicalutamide compared to vehicle treated IF
or SC tumors. Therefore, bicalutamide reduced PSA ex-
pression in the bone-niche and up-regulated AR expres-
sion while tumor growth was largely unaffected.
Bicalutamide reduced PSA levels in intra-femoral (IF)
PCSD1 tumor tissue in immunohistochemical analysis
PCSD1 was derived from a surgical prostate cancer bone
metastasis specimen obtained from a man who pre-
sented several years before with high risk (Gleason 5 + 5)
prostate cancer found to be locally advanced (T3a) and
stage 4 (2 of 5 positive lymph nodes, or N1). Pathology
on the prostatectomy tissue showed a highly undifferen-
tiated prostate adenocarcinoma with comparatively low
PSA levels that was recapitulated in the PCSD1 xeno-
graft tumors [14]. As seen in Figure 5, immunohisto-
chemical analysis of PSA in the dissected PCSD1 tumors
showed that bicalutamide treatment decreased the over-
all PSA immunostaining intensity in the intra-femorally











Figure 4 Bicalutamide reduced expression of prostate specific antigen, PSA, in intra-femoral PCSD1 tumors. Quantitative RT-PCR was
performed on RNA extracted from the intra-femoral and subcutaneous PCSD1 tumors dissected from mice treated with bicalutamide (red bars)
or vehicle control (blue bars). Quantitative RT-PCR was normalized to human-specific GAPDH expression levels. The same amount of RNA (1 ug)
was used for cDNA synthesis and yield of RNA was similar per PCSD1 and LNCaP cell. The individual mouse numbers are shown on the horizontal
axes ranked from low to high PSA level and are in the same order for all three Q-PCR plots, A-C. A.) PSA levels were higher in the IF than SC
PCSD1 tumor cells. Bicalutamide treatment decreased PSA RNA expression in IF tumors but not SC tumors. Mann Whitney test was used to
determine statistical significance (+comparison of SC vehicle to IF vehicle treatment p<= 0.016; ◆comparison of SC bicalutamide to IF bicalutamide
treatment p<=0.841; ❍ comparison of IF vehicle to IF bicalutamide treatment p<=0.008; ❖ comparison of SC bicalutamide to IF bicalutamide
treatment p<= 0.73); B.) Bicalutamide increased AR expression in SC and IF tumors (same statistical comparison groups as in A.); C.) PSMA
expression was unchanged in SC and IF tumors. Human GAPDH was used as an internal reference gene. Ratio of mean Cp of test to mean Cp
of GAPDH reference gene is shown. Mann Whitney test was used to determine there was no statistically significant difference between any of
the comparison groups. Error bars denote standard error.
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AB
Figure 5 Bicalutamide-treatment reduced PSA protein expression in intra-femoral PCSD1 tumors in immunohistochemical analysis.
Immunohistochemical analysis of PSA was performed on sections from intra-femoral and sub-cutaneous PCSD1 tumors and counterstained
with hematoxylin. Hematoxylin and eosin (H&E) and anti-PSA stains counterstained with hematoxylin were performed on fixed cryosections for
intra-femoral tumors and FFPE sections of sub-cutaneous tumors. A.) PSA immunostaining intensity was greater in vehicle than in bicalutamide
treated intra-femoral (IF) PCSD1 tumors. Magnification was 200×. B.) PSA staining was greater in vehicle than bicalutamide- treated PCSD1
intra-femoral tumors. Quantitative digital immunohistochemical analysis of PSA immunostaining intensity was performed and plotted as Total
PSA stained area/Total area of analysis. Error bars denote standard deviation.
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tumors were low in both vehicle and bicalutamide
treated mice as seen in the qPCR analysis. Semi-
quantitative analysis of digitally scanned PSA immuno-
histochemical staining intensity showed that PSA levels
were the same in SC vehicle and SC bicalutamidetreated mice whereas PSA levels were reduced in the IF
bicalutamide treated compared to IF vehicle treated tu-
mors (Figure 5B). Therefore, changes in PSA protein
levels and PSA RNA levels were consistent and demon-
strated that bicalutamide treatment reduced PSA in the
intra-femoral PCSD1 tumors.
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Androgen ablation therapy is standard for advanced
prostate cancer, however, bone metastatic prostate can-
cer (PCa) often becomes resistant to standard-of-care
therapies including androgen deprivation, radiation and
chemotherapy. Bone metastases of prostate cancers are
difficult to biopsy from patients, therefore, the currently
available clinical measures of bone metastatic prostate
cancer growth in patients are indirect: PSA in the blood
and XRays, CT scans which measure bone density or bone
scans which measure bone turnover. Changes in bone
density and turnover are used as indicators of metastatic
tumor growth. There are few pre-clinical models to under-
stand the interaction between the bone microenvironment
and prostate cancer. In order to study this directly and to
have access to the tumor tissue when it is in the bone we
established a new xenograft model of bone metastatic
prostate cancer growth, PCSD1, from a surgical prostate
cancer bone metastasis specimen (Raheem et al. [14]). We
tested the anti-androgen, bicalutamide, in PCSD1, our
new patient-derived xenograft model of bone metastatic
prostate cancer. We transplanted GFP-Luciferase express-
ing PCSD1 cells intra-femorally (IF) or sub-cutaneously
(SC) into immunodeficient mice and provided an andro-
gen deprivation challenge with Bicalutamide. We demon-
strated that, as seen in clinical trials of next generation
ADT, tumor growth in the bone niche persisted despite a
favorable biochemical PSA response. In humans receiving
ADT, bone scans have shown persistent growth despite
dropping PSA levels [13], and in our mouse model, the
Bicalutamide challenge to tumors in the bone-niche did
not prevent tumor growth despite the PSA response, while
in the subcutaneous tumor, growth slowed. Such a dis-
cordance between lowered PSA levels and uncontrolled
tumor growth in the bone–niche has also been seen in
some abiraterone-treated patients [13].
Thus, this model not only closely recapitulates anti-
androgen (castrate) resistant growth of human prostate
cancer bone metastasis but also can be used to unravel
this paradoxical role of AR in castrate-resistant PCa,
which has limited the effectiveness of all androgen
deprivation therapies. PCSD1 is a new primary prostate
cancer bone metastasis-derived xenograft model to study
metastatic disease in the bone and to develop novel ther-
apies for inhibiting androgen deprivation resistant pros-
tate cancer growth in the bone-niche.
In this paper we performed the first direct comparison
of the effectiveness of bicalutamide in inhibiting PCSD1
prostate cancer growth in the bone to when it is trans-
planted elsewhere, in this case, just beneath the skin,
or, sub-cutaneously. We found that PCSD1 tumors were
more resistant to bicalutamide treatment when growing
in the bone compared to sub-cutaneously. Importantly,
this is the first report to directly demonstrate a striking(24-fold) greater growth of prostate cancer tumors in
the bone-niche than the soft tissue, sub-cutaneous niche.
The implications of these findings are two-fold. First,
the finding that the PCSD1 mouse model closely recapitu-
lates the response in humans suggests that this is a good
model for studying castrate resistant bone metastatic pros-
tate cancer. Second, the fact that this phenomenon is
unique to the bone-niche and is not seen in the same
tumor when injected into the subcutaneous tissue con-
firms previous findings suggesting a unique interaction be-
tween prostate cancer and the bone-niche itself. We are
currently exploring possible mechanisms for this. While
the Mann–Whitney test showed that the differences in
tumor growth rates approached statistically significant p
values one limitation of this study is that additional ani-
mals in the treatment groups should be used.
A small reduction in IF tumor size in the bicalutamide-
treated compared to vehicle-treated mice can be seen at
the final time point at 18 days of treatment. However, the
difference was not statistically significant according to the
Mann–Whitney test. More mice are needed to determine
whether there is a statistically significant reduction in
PCSD1 tumor growth in the intra-femorally transplanted
tumors albeit much smaller than the response in the sub-
cutaneously transplanted tumors. While longer treatment
was not possible due to the tumors having reached the
maximal allowed tumor size according to the institutional
animal welfare protocol (IACUC), we are currently testing
whether earlier treatment may be more effective in sup-
pressing tumor growth in the bone-niche. This may
have the clinical implication that bicalutamide treat-
ment in men with any signs of bone metastasis should
commence early in the treatment plan. Such a decision
would be greatly enhanced with more sensitive, more
definitive diagnostic tests for bone metastasis. We are
using our PCSD1 model to develop improved imaging
of bone metastatic tumors.
The PCSD1 bone-niche xenograft model was derived
from a bone metastasis from a patient with castrate re-
sistant disease. PCSD1 is both PSA and AR positive by
RNA and protein analysis. Bicalutamide challenge of the
PCSD1 bone-niche model led to a decrease in tumor
PSA at the level of RNA as well as protein as seen in the
immunohistochemistry results. AR compensated by in-
creasing RNA expression. We hypothesize that cross-
talk from signaling pathways in the bone microenviron-
ment altered AR activity such that it is still functional
even in the presence of androgen deprivation therapies
such as bicalutamide. Signaling cross-talk as a mechan-
ism of castrate-resistance in prostate cancer that alters
steroid hormone receptor activity and transcriptional
regulation of gene expression has been demonstrated for
AR in as well as other steroid hormone receptors such
as GR [19-23]. Here we show for the first time that the
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rendered prostate cancer castrate resistant.
An alternative hypothesis is that the bone-niche pref-
erence and resulting increased tumor growth is due, at
least in part, to the physical enclosure of the cells within
the endosteal space in the femur compared to the sub-
cutaneous injection where the cells may disperse and,
thus, may be readily cleared from the body. This was a
concern for the IF injected cells as well since the bone
marrow is directly connected to the circulation and cells
are known to be rapidly cleared unless they have the
correct homing signals. To mitigate such a possibility in
these experiments, the SC and IF injected cells were re-
suspended 1:1 in high concentration Matrigel which rap-
idly solidifies at temperatures higher than 4°C. Once the
cells were injected sub-cutaneously, a solidified mass
could be palpated at the injection site which was main-
tained in most mice for several days to weeks so disper-
sal of the cells was not immediate, however, it was not
necessarily precluded. IVIS imaging is being performed
at early time points after initial injection in experiments
currently underway to monitor the fate of cells just after
injection both sub-cutaneously or intra-femorally. In an-
other study from our lab in which we compared bone le-
sions in mice injected intra-femorally with Matrigel/
Media alone compared to PCSD1 plus Matrigel, immu-
nohistochemical analysis revealed solidified Matrigel still
present in the endosteal space of the femurs injected
with Matrigel alone at 8 weeks post-injection (Hirata
et al., submitted). It is possible that the bone niche en-
forces and maintains close physical proximity of the
tumor cells to each other and to micro-environmental
support cells that may be just as important for providing
a growth advantage as the signals themselves.
In the near future, many urologists anticipate that
there may be a rise in the incidence of advanced prostate
cancer since the USPSTF recommendations to stop PSA
screening were released. There is no curative treatment
for bone metastatic prostate cancer. There are currently
few mouse models derived from human castrate resist-
ant bone metastases with serially transplantable mouse
xenografts into bone other than PCSD1 which was de-
veloped and characterized as previously reported [14].
Here, we confirmed that the castrate-resistant growth of
the patient bone metastasis-derived PCSD1 xenograft
occurred preferentially in the bone niche.
We investigated the effect of anti-androgen therapy for
prostate cancer in the bone versus soft tissue microenvi-
ronments using PCSD1, a new patient-derived xenograft
model for bone metastatic prostate cancer. We show for
the first time that the bone microenvironment itself sig-
nificantly increased the tumor growth capacity of the
prostate cancer cells, altered AR function and rendered
the prostate cancer castrate resistant. We demonstratedthat, as seen in a sub-set of patients in clinical trials of
next generation ADT, tumor growth in the bone niche
persisted despite a paradoxically favorable biochemical
PSA response.
Conclusions
PCSD1 is a new patient-derived primary prostate cancer
bone metastasis xenograft model from a man who devel-
oped castrate resistance metastatic disease. The xenograft
is serially transplantable via IF or SC transplantation into
Rag2−/−;γc−/− male mice, and the xenograft tumors are
positive for PSA, PSMA, and AR. We have challenged the
xenograft in this model with ADT and recapitulated non-
concordant favorable biochemical PSA response despite
continued growth in the bone niche. We have demon-
strated that this phenomenon is unique to the bone niche,
while tumor growth responded favorably to ADT in the
subcutaneous setting. Bone microenvironment permits
castrate-resistant growth in this xenograft model of bone
metastatic prostate cancer. One therapeutic implication of
our finding is that prostate cancer therapies need to target
potent survival signals that bone provides for prostate can-
cer, and we are currently working to characterize those
signals.
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